The official Spigen Amazon storefront is now offering the best price yet on its new OneTap Pro (MagFit) 3-in-1 Qi2 15W Wireless Charging Stand at $59.99 shipped. Spigen is known for delivering notable value for your money, but this has to be one of the...
Welcome to 9to5toys Battlestation Weekly – your go-to spot for the weekly roundup of the hottest deals and latest releases in PC gaming at a glance every Saturday morning. This week, we’re spotlighting massive discounts on a bunch of Razer gaming gear ...
It may be Saturday, but it’s possible your week’s work has just begun. Sure, Fortnite dropped its Week 3 quests for Absolute Doom days ago, but you got a little busy, and now you’ve got some catching up to do. If Robert Downey Jr. has taught us anythin...
EVERSPACE 2 developer ROCKFISH Games, being headquartered in Hamburg, couldn't very well pass up on the Cologne-based Gamescom, especially since they've got the Titans DLC coming up soon. Due to launch on September 16 across all platforms (PC, PlayStation 5, and Xbox Series S|X) for a price tag of $15, this is the first story DLC for the space combat game that was fully released in 2023. I caught up with ROCKFISH Games CEO and Co-Founder Michael Schade and Communications Manager Lee Guille to learn more about EVERSPACE 2: Titans and to discuss various aspects of the industry, from their […]
In what substantially bolsters the veracity of the tagline that the GLP-1 anti-obesity drugs constitute one of the most compelling cases of thematic investing this decade, UBS is out today with a fresh investment note that illustrates the scale of this ongoing paradigm shift in how the healthcare industry deals with the persistent obesity pandemic. The GLP-1 hormone suppresses hunger and regulates the production of insulin and glucose. After a meal, this hormone raises the level of insulin, which decreases blood glucose levels, and reduces the rate at which the stomach empties its contents into the small intestine, creating a […]
With potentially $100 billion in annual sales by 2030 up for grabs, the competition in the GLP-1 weight loss drugs space is predictably heating up, with Eli Lilly and Company (LLY) going head-to-head with the European pharma giant Novo Nordisk (NVO). A new study has upended the perceived parity between these two pharma heavy-weights, however, with Eli Lilly and Company managing to score a direct hit against Novo Nordisk. JAMA Study: Use Of Eli Lilly And Company's GLP-1 Agonist Tirzepatide Was Associated With Significantly Greater Weight Loss Than Novo Nordisk's Semaglutide For the benefit of those who might not be […]
From offering a viable solution to the obesity pandemic and its comorbidities to reducing the demand for ResMed's continuous Positive Airway Pressure (PAP) therapy devices that are used to treat the symptoms of sleep apnea, it is hardly surprising that GLP-1 drugs currently constitute one of Wall Street's biggest thematic investment ideas for the ongoing decade. Even so, researchers continue to discover new use-cases for these miracle drugs, with the latest such discovery centering on alcohol addiction control. A Primer On GLP-1 Drugs The GLP-1 hormone suppresses hunger and regulates the production of insulin and glucose. After a meal, this […]
Wall Street is convinced that anti-obesity GLP-1 drugs constitute a thematic bull case, with Goldman Sachs recently pegging its estimate of annual global sales of these drugs at $130 billion by 2030. In fact, financial analysts have already begun to downgrade the long-term demand outlook for fast food giants such as McDonald's, based on assumptions that 7 percent of the total population in the US would be using GLP-1 drugs in the next 10 years, with the average caloric consumption of those users declining by around 20 percent. Yet, it is the exorbitant price tags of these drugs - at […]
Eli Lilly and Company (NYSE: LLY) is currently one of the two primary darlings of Wall Street when it comes to thematic investing around anti-obesity GLP-1 drugs, with Novo Nordisk constituting the other end of this emerging duopoly. Yet, it is the precise heft of these two pharma giants that continues to present emergent opportunities to their smaller counterparts, especially in obesity-related diseases such as the Metabolic dysfunction-Associated Steatohepatitis (MASH, previously known as Nonalcoholic Ateatohepatitis or NASH). For the benefit of those who might not be aware, MASH is a fatty liver disease that develops primarily due to metabolic disorders, including […]
What if a single pharmaceutical intervention regime could not only sustainably shrink your waistline but also cure your Obstructive Sleep Apnea (OSA)? This seems too good to be true. Yet, Eli Lilly and Company's (NYSE: LLY) Tirzepatide GLP-1 drug seems to have achieved just that. Eli Lilly and Company’s "Tirzepatide Led to a Mean AHI Reduction From Baseline of 62.8% Compared to 6.4% From Baseline for Placebo," as per the Results of the SURMOUNT-OSA Study 2. To wit, Eli Lilly and Company has now announced the results of two studies that investigated the impact of its Tirzepatide GLP-1 offering on […]
Novo Nordisk (NYSE: NVO) has added billions of dollars in market capitalization over the ongoing craze around the GLP-1 anti-obesity and anti-diabetes drugs. However, the Danish pharma giant's most recognizable weight loss drug, Wegovy, is increasingly looking like a stepping stone instead of the promised panacea for the obesity pandemic. For the benefit of those who might not be aware, the GLP-1 hormone plays an important role in suppressing hunger and regulating the production of insulin and glucose. After a meal, GLP-1 agonists raise the level of insulin, which decreases blood glucose levels. Simultaneously, these drugs reduce the speed at […]
The soaring demand for GLP-1 weight loss drugs is no longer just an American or European phenomenon. As these drugs proliferate through an ever-increasing segment of the globe's obese population, the GLP-1 heavyweights such as Eli Lilly and Company and Novo Nordisk continue to reap outsized rewards. The Ozempic effect: According to Goldman Sachs, the reduction in obesity-related health concerns could boost U.S. GDP by 0.4% to 1% with widespread uptake of weight-loss medications — Julian Klymochko (@JulianKlymochko) March 3, 2024 GLP-1 drugs can induce significant weight loss by suppressing hunger and regulating the production of insulin and glucose. Eli […]
Samsung has been reported on multiple occasions to introduce a design change with the Galaxy S25 Ultra launch, with the flagship said to feature rounded corners instead of sharp ones, resembling the company’s Galaxy Note 7. However, it is one thing to check out an artist’s impression of the smartphone and another to view an actual render, and we are happy to mention that an official image has come out, but there is a catch. The notable leakster responsible for showcasing the Galaxy S25 Ultra to his fans has blurred it out unless his financial target is met. Donation goal from […]
This week saw the release of Astro Bot, a delightful game that pays tribute to the rich history of PlayStation. It also, inadvertently, highlights the dearth of new games and franchises really worth celebrating from the PS5 era. Also, Star Wars Outlaws...
In what substantially bolsters the veracity of the tagline that the GLP-1 anti-obesity drugs constitute one of the most compelling cases of thematic investing this decade, UBS is out today with a fresh investment note that illustrates the scale of this ongoing paradigm shift in how the healthcare industry deals with the persistent obesity pandemic. The GLP-1 hormone suppresses hunger and regulates the production of insulin and glucose. After a meal, this hormone raises the level of insulin, which decreases blood glucose levels, and reduces the rate at which the stomach empties its contents into the small intestine, creating a […]
With potentially $100 billion in annual sales by 2030 up for grabs, the competition in the GLP-1 weight loss drugs space is predictably heating up, with Eli Lilly and Company (LLY) going head-to-head with the European pharma giant Novo Nordisk (NVO). A new study has upended the perceived parity between these two pharma heavy-weights, however, with Eli Lilly and Company managing to score a direct hit against Novo Nordisk. JAMA Study: Use Of Eli Lilly And Company's GLP-1 Agonist Tirzepatide Was Associated With Significantly Greater Weight Loss Than Novo Nordisk's Semaglutide For the benefit of those who might not be […]
From offering a viable solution to the obesity pandemic and its comorbidities to reducing the demand for ResMed's continuous Positive Airway Pressure (PAP) therapy devices that are used to treat the symptoms of sleep apnea, it is hardly surprising that GLP-1 drugs currently constitute one of Wall Street's biggest thematic investment ideas for the ongoing decade. Even so, researchers continue to discover new use-cases for these miracle drugs, with the latest such discovery centering on alcohol addiction control. A Primer On GLP-1 Drugs The GLP-1 hormone suppresses hunger and regulates the production of insulin and glucose. After a meal, this […]
Wall Street is convinced that anti-obesity GLP-1 drugs constitute a thematic bull case, with Goldman Sachs recently pegging its estimate of annual global sales of these drugs at $130 billion by 2030. In fact, financial analysts have already begun to downgrade the long-term demand outlook for fast food giants such as McDonald's, based on assumptions that 7 percent of the total population in the US would be using GLP-1 drugs in the next 10 years, with the average caloric consumption of those users declining by around 20 percent. Yet, it is the exorbitant price tags of these drugs - at […]
Eli Lilly and Company (NYSE: LLY) is currently one of the two primary darlings of Wall Street when it comes to thematic investing around anti-obesity GLP-1 drugs, with Novo Nordisk constituting the other end of this emerging duopoly. Yet, it is the precise heft of these two pharma giants that continues to present emergent opportunities to their smaller counterparts, especially in obesity-related diseases such as the Metabolic dysfunction-Associated Steatohepatitis (MASH, previously known as Nonalcoholic Ateatohepatitis or NASH). For the benefit of those who might not be aware, MASH is a fatty liver disease that develops primarily due to metabolic disorders, including […]
What if a single pharmaceutical intervention regime could not only sustainably shrink your waistline but also cure your Obstructive Sleep Apnea (OSA)? This seems too good to be true. Yet, Eli Lilly and Company's (NYSE: LLY) Tirzepatide GLP-1 drug seems to have achieved just that. Eli Lilly and Company’s "Tirzepatide Led to a Mean AHI Reduction From Baseline of 62.8% Compared to 6.4% From Baseline for Placebo," as per the Results of the SURMOUNT-OSA Study 2. To wit, Eli Lilly and Company has now announced the results of two studies that investigated the impact of its Tirzepatide GLP-1 offering on […]
Novo Nordisk (NYSE: NVO) has added billions of dollars in market capitalization over the ongoing craze around the GLP-1 anti-obesity and anti-diabetes drugs. However, the Danish pharma giant's most recognizable weight loss drug, Wegovy, is increasingly looking like a stepping stone instead of the promised panacea for the obesity pandemic. For the benefit of those who might not be aware, the GLP-1 hormone plays an important role in suppressing hunger and regulating the production of insulin and glucose. After a meal, GLP-1 agonists raise the level of insulin, which decreases blood glucose levels. Simultaneously, these drugs reduce the speed at […]
The soaring demand for GLP-1 weight loss drugs is no longer just an American or European phenomenon. As these drugs proliferate through an ever-increasing segment of the globe's obese population, the GLP-1 heavyweights such as Eli Lilly and Company and Novo Nordisk continue to reap outsized rewards. The Ozempic effect: According to Goldman Sachs, the reduction in obesity-related health concerns could boost U.S. GDP by 0.4% to 1% with widespread uptake of weight-loss medications — Julian Klymochko (@JulianKlymochko) March 3, 2024 GLP-1 drugs can induce significant weight loss by suppressing hunger and regulating the production of insulin and glucose. Eli […]